[Form 3] Enanta Pharmaceuticals, Inc Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Enanta Pharmaceuticals (ENTA) Form 3: Harry R. Trout III reported ownership of 10,912 shares of Enanta common stock, consisting of 762 vested shares and 10,150 shares underlying unvested restricted stock units (RSUs). The RSUs vest in scheduled installments between December 1, 2025 and subsequent annual or multi-year installment schedules described in the filing. Mr. Trout also holds a series of stock options covering 53,966 underlying shares with exercise prices ranging from $8.83 to $81.20; one option grant is 100% vested and exercisable and other grants vest quarterly over four years from their grant dates. The filing was signed by an attorney-in-fact on Mr. Trout's behalf.

Positive

• Transparent disclosure of direct shares, RSUs and multiple option grants with specific vesting and exercise-price details
• One option grant fully vested and exercisable, indicating available exercised-alignment potential for the reporting person

Negative

• None.

Insights

Financial Analyst

TL;DR: Insider holds a modest direct stake plus sizable option and RSU awards with staggered vesting.

The filing discloses that Mr. Trout directly owns 762 shares and beneficially owns 10,150 RSUs that convert to common stock upon vesting, producing a reported total of 10,912 shares. The disclosure lists seven option grants totaling 53,966 underlying shares with exercise prices between $8.83 and $81.20; one grant is fully vested while the others vest quarterly over four years from their grant dates. For investors, this shows ongoing equity-based compensation alignment without revealing transactions or sales.

Corporate Governance Expert

TL;DR: Standard Section 16 disclosure of executive beneficial ownership and scheduled equity vesting.

The Form 3 is an initial beneficial ownership statement showing officer status (Vice President, Finance) and details of equity awards subject to Enanta's 2019 Equity Incentive Plan. The RSU vesting schedule is specified in detail with installment dates beginning December 2025. Signature was provided via power of attorney. The form contains routine, required disclosures and no indications of immediate related-party transactions or departures.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Trout Harry R. III

(Last) (First) (Middle)

C/O ENANTA PHARMACEUTICALS, INC.

4 KINGSBURY AVENUE

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/26/2025

3. Issuer Name and Ticker or Trading Symbol
ENANTA PHARMACEUTICALS INC [ ENTA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Vice President, Finance

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	10,912(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(2)	11/16/2028	Common Stock	7,110	$81.2	D
Stock Option (right to buy)	(2)	11/18/2029	Common Stock	10,000	$63.35	D
Stock Option (right to buy)	(2)	11/20/2030	Common Stock	4,987	$43.57	D
Stock Option (right to buy)	(3)	11/19/2031	Common Stock	6,048	$75.33	D
Stock Option (right to buy)	(4)	11/23/2032	Common Stock	5,571	$45	D
Stock Option (right to buy)	(5)	11/22/2033	Common Stock	9,075	$8.99	D
Stock Option (right to buy)	(6)	11/27/2034	Common Stock	10,175	$8.83	D

Explanation of Responses:

1. Consists of 762 shares of common stock held by the reporting person and 10,150 shares of common stock underlying unvested restricted stock units ("RSUs") granted under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs will vest and settle as follows: (i) 359 RSUs will vest and settle on December 1, 2025, (ii) 1,300 RSUs will vest and settle in two substantially equal annual installments beginning on December 4, 2025, (iii) 3,403 RSUs will vest and settle in three substantially equal annual installments beginning on December 4, 2025, and (iv) 5,088 RSUs will vest and settle in four substantially equal annual installments beginning on December 1, 2025.

2. 100% of the shares subject to the option are fully vested and exercisable.

3. Such option has or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021).

4. Such option has or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 23, 2022).

5. Such option has or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 22, 2023).

6. Such option has or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024).

Remarks:

Exhibit 24 Power of Attorney filed herewith.

	/s/ Matthew Kowalsky as attorney-in-fact	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What total number of Enanta (ENTA) shares does Harry R. Trout III report owning?

The Form 3 reports 10,912 shares beneficially owned, consisting of 762 direct shares and 10,150 shares underlying RSUs.

How many stock options does Mr. Trout hold and what are the exercise prices?

The filing lists options underlying 53,966 shares with exercise prices of $81.20, $63.35, $43.57, $75.33, $45.00, $8.99, and $8.83.

When do the RSUs reported by Mr. Trout vest?

The RSUs vest in installments: 359 RSUs on December 1, 2025; 1,300 RSUs in two annual installments beginning December 4, 2025; 3,403 RSUs in three annual installments beginning December 4, 2025; and 5,088 RSUs in four annual installments beginning December 1, 2025.

Is any option fully vested and exercisable?

Yes. The filing states that 100% of the shares subject to one option grant are fully vested and exercisable.

Who signed the Form 3 filing for Mr. Trout?

The Form 3 was signed by Matthew Kowalsky as attorney-in-fact on behalf of the reporting person.